SERUM PROTEIN PROFILES DIFFER WITH USTEKINUMAB AND ADALIMUMAB TREATMENT IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Swati Venkat  1     Martha Zeeman  1     Amy Hart  1     Sunita Bhagat  1     Dylan Richards  1     David A. Galbraith  1     Timothy Hoops  2     Paul Ufberg  2     James Izanec  3     Thomas C. Freeman  3     Bradford McRae  3     Shinichiro Shinzaki  4     Vipul Jairath  5     Remo Panaccione  6     Bruce E. Sands  7     Patrick Branigan  7    
1 Janssen Research & Development, LLC, Spring House, United States
2 Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, United States
3 Janssen Pharmaceuticals, LLC, Horsham, United States
4 Hyogo Medical University, Nishinomiya, Hyogo, Japan
5 University Hospital, London, Canada
6 University of Calgary, Calgary, Canada
7 Icahn School of Medicine at Mount Sinai, New York, United States

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing